Incidence and characteristics of spontaneous platelet macro-aggregation in acute ischemic stroke

Tomohiro Osanai1, Kasumi Mikami2, Maiko Kitajima2

  • 1Department of Nursing Science, Hirosaki University Graduate School of Health Science, 66-1 Hon-cho, Hirosaki, 036-8564, Japan. osanait@hirosaki-u.ac.jp.

Insights

Spontaneous platelet macro-aggregation (SPMA) occurs in 1.5% of acute ischemic stroke patients and is linked to worse functional outcomes. This condition, unlike micro-aggregation, is not effectively treated by standard anti-platelet medications.

Area of Science:

  • Cardiovascular Research
  • Neurology
  • Hematology

Background:

  • Spontaneous platelet aggregation contributes to thrombus formation.
  • Micro-aggregation is common in diabetes and responsive to P2Y12 inhibitors.
  • Macro-aggregation involves platelet α2-adrenoreceptors and resists conventional anti-platelet drugs.

Purpose of the Study:

  • To investigate the incidence of spontaneous platelet macro-aggregation (SPMA) in acute ischemic stroke.
  • To analyze the clinical characteristics and outcomes of stroke patients with SPMA.

Main Methods:

  • Retrospective analysis of 665 consecutive acute ischemic stroke patients.
  • Comparison of SPMA incidence between stroke patients and 588 control subjects.
  • Assessment of clinical characteristics, stroke types, and functional outcomes using modified Rankin Scale (mRS).

Main Results:

  • SPMA was detected in 1.5% of acute ischemic stroke patients, with none in controls.
  • Stroke patients with SPMA showed significantly worse mRS scores at discharge (3.00 ± 0.53 vs 1.93 ± 0.07).
  • Patients with SPMA had lower functional independence at discharge (mRS 0-2) and poorer outcomes, especially in atherothrombotic stroke cases, despite anti-platelet therapy.

Conclusions:

  • SPMA is a distinct clinical entity in acute ischemic stroke, associated with poorer functional outcomes.
  • SPMA is more prevalent in older patients with major disabilities, leading to less functional improvement.
  • Current anti-platelet therapies appear less effective in mitigating the negative impact of SPMA on stroke recovery.

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.4K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
938